Hey Giose
All lines up nicely IMO
conclusion
Repurposing existing therapies will be the quickest way to find effective intervention and improve outcomes in COVID-19; however, bigger gains are likely through the development of new agents specific to SARS-CoV2. These are being rapidly engineered using high-throughput screening platforms. Websites tracking COVID-19 clinical trials and the development of new agents show over 300 novel agents are in pre-clinical testing. Their diverse actions reflect the range of pathology seen in COVID-19 that is a consequence of both viral action as well as immune response. Their introduction into clinical trials will be the next exciting phase of therapeutics.
Biotron Announcement 7 September 2020
BIOTRON COMPOUNDS SHOW ACTIVITY AGAINST SARS-CoV-2 VIRUS IN PRELIMINARY
ASSAYS
The Company’s focus will now be on building on this preliminary stage screening program to include a new series
of recently designed and synthesised compounds. Screening of these additional new compounds is expected to
conclude before the end of 2020. It is hoped that within these new compounds there will be potent, druggable
compound(s) that can be progressed to testing in animal models of COVID-19 disease and ultimately clinical trials
$10 Billion Deal, page-7899
-
- There are more pages in this discussion • 5,426 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.14M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.9¢ | $7.664K | 403.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1202498 | 5 |
View Market Depth
| Last trade - 13.42pm 27/09/2024 (20 minute delay) ? |
| BIT (ASX) Chart |